- Home
- ABTS vs GDTC Comparison
ABTS vs GDTC Comparison
Compare ABTS & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABTS | GDTC |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | Hong Kong | Singapore |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1M | 15.5M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | ABTS | GDTC |
|---|---|---|
| Price | $5.53 | $0.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.2K | ★ 38.4K |
| Earning Date | 08-13-2025 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,384,971.00 | $573,193.00 |
| Revenue This Year | N/A | $5.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 22.52 | ★ 63.03 |
| 52 Week Low | $1.35 | $0.89 |
| 52 Week High | $10.86 | $3.68 |
Technical Indicators
Market Signals| Indicator | ABTS | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 43.77 | 20.48 |
| Support Level | $5.24 | $0.89 |
| Resistance Level | $6.03 | $1.39 |
| Average True Range (ATR) | 0.30 | 0.13 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 30.46 | 7.13 |
Price Performance
Historical ComparisonAbout ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.